A Look at Precigen's (PGEN) Valuation Following FDA Approval of PAPZIMEOS

Simply Wall St.

Oct 28, 2025

Precigen (PGEN) has drawn attention after the FDA granted full approval to PAPZIMEOS, its immunotherapy for adults with recurrent respiratory papillomatosis. The therapy's pivotal study showed a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578600789"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578600789\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578600789?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-10-28 09:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578600789","market":"nz","top_or_hot":-1,"title":"A Look at Precigen's (PGEN) Valuation Following FDA Approval of PAPZIMEOS","media":"Simply Wall St.","content":"<div>\n<p>Precigen (PGEN) has drawn attention after the FDA granted full approval to PAPZIMEOS, its immunotherapy for adults with recurrent respiratory papillomatosis. The therapy's pivotal study showed a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pgen/precigen/news/a-look-at-precigens-pgen-valuation-following-fda-approval-of\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look at Precigen's (PGEN) Valuation Following FDA Approval of PAPZIMEOS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look at Precigen's (PGEN) Valuation Following FDA Approval of PAPZIMEOS\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-28 09:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pgen/precigen/news/a-look-at-precigens-pgen-valuation-following-fda-approval-of><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Precigen (PGEN) has drawn attention after the FDA granted full approval to PAPZIMEOS, its immunotherapy for adults with recurrent respiratory papillomatosis. The therapy's pivotal study showed a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pgen/precigen/news/a-look-at-precigens-pgen-valuation-following-fda-approval-of\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGEN","symbol_name":"Precigen","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pgen/precigen/news/a-look-at-precigens-pgen-valuation-following-fda-approval-of","article_id":"2578600789","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pgen/precigen/news/a-look-at-precigens-pgen-valuation-following-fda-approval-of","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2578600789","pubTimestamp":1761614696,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Precigen (PGEN) has drawn attention after the FDA granted full approval to PAPZIMEOS, its immunotherapy for adults with recurrent respiratory papillomatosis. The therapy's pivotal study showed a meaningful patient response and set a new benchmark in the field.\nSee our latest analysis for Precigen.\nAfter a challenging few years, Precigen’s fortunes have quickly turned. Share price momentum has exploded since January, driven by catalysts like the PAPZIMEOS approval and positive trial updates...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"PGEN":"Precigen","BK4139":"生物科技"},"translate_title":"FDA批准PAPZIMEOS后Precigen(PGEN)的估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGEN":1.5},"content_text":"Precigen (PGEN) has drawn attention after the FDA granted full approval to PAPZIMEOS, its immunotherapy for adults with recurrent respiratory papillomatosis. The therapy's pivotal study showed a meaningful patient response and set a new benchmark in the field. See our latest analysis for Precigen. After a challenging few years, Precigen’s fortunes have quickly turned. Share price momentum has exploded since January, driven by catalysts like the PAPZIMEOS approval and positive trial updates for other pipeline therapies. Momentum is clearly building, with a 1-year total shareholder return of 409% reflecting renewed market confidence in the company’s long-term growth prospects. If you’re interested in discovering more fast movers in the biotech space, it’s a great time to check out See the full list for free. With Precigen’s share price soaring and Wall Street forecasting further gains, the key question for investors is whether there is real value left on the table or if the market has already factored in all that future growth. AdvertisementPrice-to-Book of -34.8x: Is it justified? Precigen currently trades at a price-to-book ratio of -34.8x, which is deeply negative and highly unusual compared to sector averages and peers. The price-to-book ratio compares a company's market value to its book value, offering a window into how investors are valuing the business's assets versus its stock price. A negative ratio signals that liabilities exceed assets, which is notable for a biotech company and adds a layer of complexity for would-be investors. Peer companies in the US Biotechs sector average a 2.5x price-to-book, while Precigen’s negative equity profile makes any direct comparison difficult and renders traditional valuation methods less relevant. With book value negative, the market may be pricing in future growth or expecting a turnaround. However, such a gap warrants careful attention. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-Book of -34.8x (ABOUT RIGHT) However, weak profitability and a heavily negative net income may limit upside if revenue growth falters or if competitive pressures intensify in the biotech space. Find out about the key risks to this Precigen narrative.  Build Your Own Precigen Narrative If you’d like a different perspective or prefer diving into your own research, you can quickly shape your own view using the latest data. Do it your way A great starting point for your Precigen research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision. Looking for More Smart Investment Opportunities? Don’t let your money sit idle while others are seizing tomorrow’s biggest gains. Tap into winning ideas ready to reshape your portfolio’s future right now:  Maximize your income by targeting strong yields with these 19 dividend stocks with yields > 3%. This opportunity delivers over 3% payouts and consistent returns. Capitalize on game-changing industries and ride the next wave of innovation with these 27 AI penny stocks. These stocks are set to disrupt markets with artificial intelligence breakthroughs. Spot undervalued gems primed for growth, and access companies trading below their intrinsic worth using these 875 undervalued stocks based on cash flows to keep your edge sharp.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}